Hizentra® in Inflammatory Neuropathies - pHeNIx Study
Latest Information Update: 23 Apr 2024
At a glance
- Drugs Immune globulin (Primary) ; Immune globulin
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Therapeutic Use
- Acronyms pheNIX
- Sponsors CSL Behring
- 18 Apr 2024 Planned End Date changed from 1 Sep 2024 to 1 Dec 2027.
- 18 Apr 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Dec 2027.
- 06 May 2022 Planned initiation date changed from 1 Mar 2022 to 1 May 2022.